Are Peptides Legal? Regulatory Status in the USA, Europe, Australia & Canada (2026)

There is no single answer. "Legal" resolves into four independent questions, a compound can sit differently on each, and most of the confusion in this market lives in the gap between them.

This page is a status snapshot as of August 2026, organised by those four axes, and it names the countries where documents exist rather than generalising to the rest. The dated sequence behind the US position is in the FDA peptide regulation timeline, and the mechanics of the one lawful supply route in compounding pharmacy versus research peptide.

Is there one answer to whether a peptide is legal?

No, there are four, and they move independently. A compound may be approved as a medicine somewhere; it may be unapproved but lawfully compoundable in the United States under a statutory prong; it may be unapproved with no compounding route at all; and it may be prohibited in sport regardless of any of that. Tesamorelin occupies three of those positions simultaneously — approved, compoundable, and prohibited under WADA section S2.2.4.

Two consequences follow, and both are routinely got wrong. An approval in one country is not an approval in another — mazdutide is a licensed medicine in China and an unapproved new drug in the United States, on the same day. And absence from a regulator's list is not permission: most peptides appear on no FDA compounding table at all, because nobody ever nominated them, which means the agency has never looked rather than that it looked and cleared them.

This is legal information, not legal advice. It states what published documents say. For anything touching your own position, a qualified professional in your own jurisdiction is the only useful source.

Which countries does this article have documented facts for?

Six, at very different depths, and that is the honest extent of it. The United States is covered in depth. Ireland, the United Kingdom, Australia and Denmark are covered through specific published agency actions on specific compounds, not through general legal analysis. Russia and China appear as approval jurisdictions — registration certificates and marketing authorisations — with no enforcement record here. Everywhere else is undocumented in this record, and this page does not guess.

The EMA and the TGA also appear across this corpus in a narrower form — as statements that a given compound is not approved by them, which is an absence rather than a finding. CJC-1295 and AOD-9604 are not approved by the FDA, the EMA or the TGA, and that is as far as the record goes for those two agencies on those compounds.

Padding this out to a global survey would mean inventing it, which is the exact failure mode this platform exists to correct. A compound's status in Canada, Germany, Japan beyond one diagnostic licence, India or the Gulf is not established here in either direction.

Which peptides hold a marketing authorisation, and where?

Fewer than the market implies, and the indications are narrow. In the United States, tesamorelin, bremelanotide, afamelanotide, elamipretide, semaglutide, tirzepatide and oxytocin are approved medicines. Mazdutide is approved only in China, under two authorisations from June and September 2025. Semax, Selank and Thymalin hold Russian registrations. GHRP-2 is licensed in Japan as a diagnostic agent. Everything else this platform covers is approved nowhere.

Read the indication column rather than the approval column. An approval is for a population and a purpose, not for a molecule. Bremelanotide's label carries FDA's own Limitations of Use: it is "not indicated for treatment of HSDD in postmenopausal women or in men," and "not indicated to enhance sexual performance" — which excludes most of what the compound is bought for. Elamipretide is approved for Barth syndrome in patients over 30 kg for muscle strength, not for mitochondrial health generally.

The Chinese record deserves its own note because it is the newest and the most misreported. Shirley M, "Mazdutide: First Approval," Drugs, December 2025 (PMID 41028652), records that "in June 2025, mazdutide received its first approval, in China" for weight management, and that "subsequently, in September 2025, mazdutide also received approval in China for use in glycaemic control in adults with T2D." A Lancet Diabetes & Endocrinology review of obesity in China (PMID 41389801) corroborates it. Mazdutide's status in markets other than China and the United States we could not confirm in either direction.

Which unapproved peptides can a US pharmacy lawfully compound?

Very few, and only through one of three statutory prongs. Under 21 U.S.C. § 353a(b)(1)(A), a bulk substance used in 503A compounding must comply with an applicable USP or NF monograph, be a component of an FDA-approved drug, or appear on FDA's 503A bulks list. That list holds six substances and none of them is a peptide. Gonadorelin qualifies on the first prong, sermorelin and tesamorelin on the second, oxytocin on both. Most peptides satisfy none.

One honest caveat travels with sermorelin. Both Geref approvals were formally withdrawn in 2009, and we found no FDA document expressly resolving whether a withdrawn approval still satisfies that prong. The 503B footnote implies the agency's answer; the final inferential step is not spelled out anywhere we could locate, and we are not going to pretend otherwise.

Qualifying under a prong is a statutory pathway, not an efficacy endorsement, and it is not a licence for a vial bought online. It permits a licensed pharmacist to prepare the substance for a named patient with a prescription. FDA's own language limits even that route: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."

Which peptides are unapproved with no compounding route?

Most of them, by a wide margin, and for three distinguishable reasons. Some sit on FDA's active Category 2 list, blocked pending evaluation: GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10. Some were nominated and then withdrawn by their nominators, which is procedural rather than a clearance. And most were never nominated at all, so FDA has never looked — an absence that carries no permission whatsoever.

The fourth and fifth rows are the ones vendor copy gets backwards most often. Compounding a drug that is essentially a copy of an approved product is permitted only while that product is in shortage. FDA's shortage database now lists both Tirzepatide Injection and Semaglutide Injection as "Resolved," and enforcement discretion ended on 22 April 2025 for 503A pharmacies and 22 May 2025 for 503B outsourcing facilities. Belcourt, Sapowadia & White, in Annals of Pharmacotherapy, state the consequence: "With the shortage of innovator semaglutide or tirzepatide products resolved, compounding pharmacies can only legally sell unique products."

A compound never approved anywhere in the United States has never been in shortage there, so no route has ever existed for it. That applies to retatrutide, survodutide, cagrilintide and mazdutide alike.

On scheduling, one class stands apart. DEA's controlled substances list, revised 25 June 2026, records "Anabolic steroids | 4000 | III" under the statutory definition at 21 U.S.C. §802(41)(A), a chemical-relationship test rather than an effect test. Performance peptides and SARMs are unapproved drugs, which is a regulatory category rather than a criminal one — a distinction developed in peptides versus SARMs versus steroids.

Which peptides are prohibited in sport, and under which section?

Many that are otherwise unremarkable, and the register is entirely separate from any national approval. WADA's 2026 Prohibited List names gonadorelin and kisspeptin at S2.2.1, GHRH analogues including sermorelin and tesamorelin at S2.2.4, IGF-1 and its analogues, mechano growth factors and thymosin-β4 at S2.3, and follistatin at S4.3. The S0 catch-all reaches substances with no approval from any governmental health authority. GLP-1s are not prohibited.

The structural correction in that table matters as much as the content. Older editions divided S1.1 into lettered subsections separating exogenous from endogenous steroids. The 2026 list does not. Material citing S1.1a or S1.1b is citing an edition that no longer exists.

Two entries are genuinely ambiguous and should not be reported as settled. Semax is not named on the 2026 list, and S0 turns on having no approval from any governmental health authority — Semax holds a Russian one, which on the literal wording places it outside S0. No anti-doping authority has published a determination. Mazdutide is in the same position through its Chinese approval. An athlete needs a ruling from their own anti-doping organisation, not a forum opinion or this page.

What have regulators outside the United States published?

Four agencies have published direct findings, all of them on melanotan II, and their language is unusually blunt. Ireland's HPRA stated on 10 August 2023 that it is "not authorised by the HPRA or any medicines regulator to treat any condition," removing more than 500 listings between July 2022 and June 2023. Australia's TGA issued 27 infringement notices totalling $101,412 on 21 May 2026. The MHRA and Denmark's Lægemiddelstyrelsen have published equivalent findings.

Ireland — HPRA, 10 August 2023. The product is "not authorised by the HPRA or any medicines regulator to treat any condition," and the agency removed more than 500 listings in the year from July 2022 to June 2023.

United Kingdom — MHRA, FOI response 24/274, 17 April 2024. "Products containing Melanotan II are classified as medicines if they are injectable or pens," and "the sale, supply and advertising of unauthorised medicines is not permitted." The agency received 16 UK Yellow Card adverse drug reaction reports between 2012 and 2022 and has "repeatedly taken action to remove Melanotan products from the market for over 10 years."

Australia — TGA, 21 May 2026. Twenty-seven infringement notices totalling $101,412, with the agency stating there are "no products containing Melanotan II on the Australian Register of Therapeutic Goods."

Denmark — Lægemiddelstyrelsen, 20 June 2011, restating a 2008 alert. The agency warns against the product "because the effect is not documented, and because studies of possible side effects are lacking," describing it as approved neither in Denmark, Europe, nor the USA.

United States — FDA, Notice of Opportunity for Hearing, 5 August 2016. Melanotan II "constituted a new drug under the FDCA that could not be introduced or delivered for introduction into interstate commerce without an FDA approved application." The action followed a seller who continued shipping after a 2007 warning letter, made therapeutic claims about reducing skin cancer risk and curing rosacea, and advertised the product as "100% U.S. made" while importing from China.

That five-agency record exists for melanotan II and, in this corpus, for no other compound. Its usefulness is as a demonstration of what published regulatory findings look like, not as a template that can be assumed for peptides no agency has commented on.

Does "research use only" labelling change the position?

No, and FDA has tested that proposition on a named compound. A warning letter dated 10 December 2024 to Xcel Research LLC named seven products including sermorelin. Despite labelling reading "FOR RESEARCH USE ONLY" and "NOT INTENDED FOR HUMAN USE," FDA held the products were unapproved new drugs violating sections 505(a) and 301(d) of the Food, Drug and Cosmetic Act, because website evidence established human intended use. The disclaimer described the label, not the transaction.

FDA's general statement is broader than that single letter. The agency "has warned companies that have illegally sold unapproved drugs... falsely labeled 'for research purposes' or 'not for human consumption.' These products have been sold directly to consumers for human use." On salt forms, FDA adds that these "are different active ingredients than are used in the approved drugs" — which means a vial of semaglutide sodium is not, in the agency's view, the substance in the approved product at all.

Note what that does and does not establish. The enforcement in this record runs against sellers, through warning letters, notices of opportunity for hearing and infringement notices. This page does not address the position of a purchaser in any jurisdiction, because the documents here do not, and that is a question for a qualified professional rather than an article.

What separates an approved peptide from an unapproved one, chemically?

Sometimes about one dalton. Bremelanotide is an FDA-approved medicine at 1,025.2 Da under NDA 210557; melanotan II is approved in no country at 1,024.18 Da, and five agencies have published findings against it. That is a separation of roughly 1.0 dalton on 1,025, under 0.1%, which is below what HPLC purity testing or nominal-mass mass spectrometry can resolve. Legal status and molecular similarity are unrelated variables.

The asymmetry is worth stating because it decides who bears the risk. A buyer paying for bremelanotide and receiving melanotan II has bought a compound with a two-decade adverse case literature and no approval anywhere; the reverse substitution costs a melanotan II buyer nothing. A purity certificate cannot tell those two molecules apart, which makes the legal difference invisible to the document most buyers rely on.

Which claims about peptide legality survive the record?

Three of nine. Peptides are not controlled substances in the United States, unapproved status is a regulatory category rather than a criminal one, and a handful of compounds genuinely are compoundable — those hold. The rest do not survive: "legal in Europe," "approved in Russia so approved abroad," "removed from Category 2 means cleared," and "research use only makes it lawful" are each false in a specific, documented way.

How do you check the status of a specific compound?

Name the axis first, then the jurisdiction, then the date. Almost every wrong answer in this market comes from collapsing four questions into one, or from quoting a US position to a reader outside the US. A status claim that does not say which of the four axes it describes has not answered anything, and a claim with no date attached cannot be checked at all, because at least four positions in this record moved between September 2023 and July 2026.

What does the platform data show on a compound approved nowhere?

A high purity figure attached to the wrong question. The Purity Index records melanotan II at 99.62% across 251 independent tests from ILS, MZ Biolabs, Kovera, Janoshik and Freedom Diagnostics, across 226 verified shops (verified August 2026) — a compound with published findings against it from five national regulators and no approval anywhere. Quantity variance runs −7.3% to +16% and endotoxin results are mostly absent.

Melanotan II price data shows 69 shops in stock at a median of $3.80 per milligram, lowest $1.50/mg on a 10 mg vial and highest $9.00/mg, from 173 known shops (verified 10 August 2026). Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing. Peptigrity tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026), weighting community reviews and independently verified purity equally at 50% each.

The lesson is one this platform has to state about its own largest asset. A purity percentage is silent on legal status, and it is silent on the harms that produced the regulatory findings, because the published cases occurred with correctly identified, homogeneous material. Listings sit on the melanotan II compound page and individual certificates in the lab test database.

The trial that would settle the global picture

No comprehensive cross-jurisdictional survey of peptide legal status exists, and the coverage table above is a demonstration of why that gap matters. The four axes are established and the United States is well documented; what is missing is a systematic reading of national drug registers and published enforcement records beyond the six jurisdictions named here. It is archival work rather than laboratory work, it would take a language-capable team a year, and nobody has funded it.

Frequently Asked Questions

Is it illegal to buy peptides?

That is not one question, and this page cannot answer it for your jurisdiction. What the documents establish is that most peptides are unapproved new drugs rather than controlled substances, that FDA's enforcement in this record runs against sellers through warning letters and notices of opportunity for hearing, and that agencies in Ireland, the UK, Australia and Denmark have taken action against supply. Anything about your own position is a question for a qualified professional.

Are peptides legal in the UK?

The record here covers one compound. The MHRA stated in FOI response 24/274 of 17 April 2024 that products containing melanotan II are "classified as medicines if they are injectable or pens," that "the sale, supply and advertising of unauthorised medicines is not permitted," and that it has acted repeatedly against these products for over ten years. This corpus does not carry a general UK legal analysis, and extending that one finding to other compounds would be a guess.

Does approval in Russia or China make a peptide legal elsewhere?

No. Marketing authorisations are national. Mazdutide holds two Chinese approvals and remains an unapproved new drug in the United States. Semax is a registered medicine in Russia on the essential medicines list and is not approved in the US or the EU. The one place a foreign approval does change something is WADA's S0 clause, which reaches substances with no approval from any governmental health authority.

Which peptides can a pharmacy legally compound in the US?

Only those satisfying one of the three prongs at 21 U.S.C. § 353a(b)(1)(A): compliance with a USP or NF monograph, status as a component of an FDA-approved drug, or a place on FDA's 503A bulks list. Gonadorelin qualifies through its monographs, oxytocin through both of the first two, and tesamorelin and sermorelin as components of approved drugs. The bulks list itself holds six substances and none is a peptide.

Does a compound coming off FDA's Category 2 list mean it is now allowed?

No. FDA's page carries two tables, and the second exists because, in the agency's own words, the substances "were withdrawn by the nominators." That is a procedural act by whoever filed the nomination, not a safety clearance, and FDA's published concerns often remain visible alongside the entry. Nothing about a compound's compounding eligibility changes when it moves between those tables.

Are GLP-1 drugs banned in sport?

No. Semaglutide, tirzepatide and orforglipron do not appear on WADA's 2026 Prohibited List, and no GLP-1 class entry exists. That is a different answer from the growth hormone secretagogues and growth factors, which are prohibited at all times under S2.2.4 and S2.3. Anti-doping status tracks mechanism and approval, not popularity or route of administration.

Where this leaves the question

"Are peptides legal" cannot be answered without naming an axis, a country and a date. On the axis of approval, a short list of compounds holds narrow licences in the US, two in Russia, one in China and one diagnostic licence in Japan. On compounding, four compounds reach a statutory prong and the rest do not. On sport, a long list is prohibited at all times regardless of any of that.

The honest limit of this page is its geography. Six jurisdictions are documented here, four of them through a single compound, and the rest of the world is not covered in either direction. That is a smaller answer than most pages on this subject give, and it is the size the evidence supports.

Browse the libido and sexual wellness peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For per-injection volume, use the peptide dosing calculator alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.